Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody

Torsten Dreier, Grit Lorenczewski, Christian Brandl, +7

International Journal of Cancer

ImmunologyImmunologic MechanismCd4 T Cell ResponsesImmune Cell TherapyImmunotherapy +17

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans

Peter Ulrichts, Antonio Guglietta, Torsten Dreier, +13

Journal of Clinical Investigation

Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritis

Ken Coppieters, Torsten Dreier, Karen Silence, +12

Arthritis & Rheumatism

Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

Bernard M. Tijink, Toon Laeremans, Marianne Budde, +5

Molecular Cancer Therapeutics

NanoparticlesNanotherapeuticsEngineeringImmunologyTaking Advantage +19

Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis

Klaas Vandenbroucke, Hans de Haard, Els Beirnaert, +9

Mucosal Immunology

InflammationNanomedicineAnti-inflammatoryChronic ColitisEngineering +8

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

James F. Howard, Vera Bril, Ted M. Burns, +20

Neurology

T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct

Torsten Dreier, Patrick A. Baeuerle, Iduna Fichtner, +8

The Journal of Immunology

Lymphoid NeoplasiaCancer ImmunosurveillanceTherapeutic EffectT Cell Costimulus-independentBispecific Ab +12

Natural Killer Cell–Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy

Holger N. Lode, Rong Xiang, Torsten Dreier, +3

Blood

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia

Adrian C. Newland, Blanca Sánchez‐González, László Rejtő, +14

American Journal of Hematology

High-throughput generation and engineering of recombinant human antibodies

Barbara Krebs, Robert Rauchenberger, Silke U. Reiffert, +16

Journal of Immunological Methods

EngineeringMedicineImmunologyGenetic EngineeringSynthetic Biology +6